SOPHiA GENETICS (SOPH) Q4 2025 earnings summary

Executive summary

• Achieved 22% year-over-year revenue growth in Q4 2025 and 19% for the full year, with $77.3M revenue and strong momentum in clinical and biopharma segments.

• Connected over 993 global customers, including 124 new customers in 2025 and two major U.S. health systems; performed 391,000+ analyses.

• Signed major BioPharma contracts, including the largest project with AstraZeneca and a new top 5 global pharmaceutical company.

• U.S. market remains underpenetrated but grew 50% YoY in Q4 2025, with analysis volume up 27% for the year.

• Highly recurring revenue model with <1% annualized revenue churn and 115% net dollar retention in 2025.

Financial highlights

• FY 2025 revenue reached $77.3M, up 19% YoY; Q4 2025 revenue was $21.7M, up 22% YoY.

• Adjusted gross margin was 74.2% in FY 2025, up 140 bps YoY; reported gross margin was 67.4%.

• Adjusted EBITDA loss for FY 2025 was $41.5M; adjusted operating loss was $45.5M.

• Cash and equivalents at year-end were $70.3M, excluding $14.4M raised in Q1 2026.

• Raised $15.5M via ATM facility and expanded credit facility by $25M.

Outlook and guidance

• FY 2026 revenue guidance: $92M–$94M (20–22% growth), with growth weighted to the second half as new business ramps.

• Adjusted EBITDA loss expected between $29M and $32M for FY 2026, with gross margin expansion and improved operating leverage.

• Targeting adjusted EBITDA breakeven by end of 2026 and positive adjusted EBITDA in H2 2027.

• Expects continued growth in U.S. market and expansion of new applications such as Liquid Biopsy.

• Industry forecasts indicate NGS market CAGR of ~7% (2025-2026) and global genetic testing CAGR of 20%+ by 2030.